Hereditary Hemorrhagic Telangiectasia (HHT) Center
This funding opportunity provides financial support to a variety of organizations to improve coordinated care and research for individuals affected by a rare genetic disorder that causes abnormal blood vessel formation.
Description
The Hereditary Hemorrhagic Telangiectasia (HHT) Center grant, offered by the Health Resources and Services Administration (HRSA) under the Department of Health and Human Services, aims to reduce the morbidity and mortality associated with HHT. This initiative will focus on expanding access to coordinated care for individuals with HHT while simultaneously developing a de-identified, aggregate patient data registry to enhance the understanding of the disease and treatment outcomes. The program is designed to improve healthcare services for HHT patients through better coordination and data collection.
This funding opportunity falls under the Maternal and Child Health Federal Consolidated Programs, with an assistance listing number of 93.110. The grant will be awarded as a cooperative agreement, allowing HRSA to have substantial involvement in project implementation. The opportunity is categorized under the health sector, reflecting its focus on addressing healthcare gaps and improving patient outcomes for those affected by this rare genetic disorder.
A total of $1,800,000 in funding is anticipated for this grant, though specific award ceiling and floor amounts have not been provided. Only one award is expected to be granted, ensuring that the funding is dedicated to a single, well-coordinated initiative. Cost-sharing or matching funds are not required for applicants, making this an accessible opportunity for a wide range of eligible entities.
Eligible applicants for this grant include public entities, institutions of higher education, tribes and tribal organizations, for-profit organizations, small businesses, and nonprofit organizations. This broad eligibility criterion ensures that a diverse group of stakeholders can contribute to improving care and research for HHT. The successful applicant will be expected to implement strategies to enhance patient access to care while also collecting and analyzing de-identified patient data.
The estimated timeline for this grant includes a forecasted date of July 25, 2024, and an estimated post date of April 21, 2025. The estimated application due date is June 20, 2025, with the anticipated project start date on September 1, 2025. Given that this is a forecasted opportunity, these dates may be subject to change as the official Notice of Funding Opportunity (NOFO) is released.
For more information, applicants can contact Nordia Williams at (240) 475-3310 or via email at Nwilliams1@hrsa.gov. Further details regarding application requirements and evaluation criteria are expected to be provided when the official grant opportunity is published.